Fenbendazole and the Joe Tippens Protocol (2026): Evidence, Risks, and Current Perspective
Medically Reviewed by: Dr Frank Yap, MD | Written by: OneDayMD Editorial Team | Last Updated: September 2026
Introduction
.png "Fenbendazole and the Joe Tippens Protocol")
What is the Joe Tippens Protocol?
Joe Tippens' Story – Key Facts and Context
- Diagnosed in 2016 with small-cell lung cancer metastasized to multiple organs; given ~3 months to live.
- Enrolled in a pembrolizumab (Keytruda) clinical trial at MD Anderson (immunotherapy drug now known to produce durable remissions in some patients).
- Started fenbendazole (222 mg/day) + supplements after hearing an anecdotal report from a veterinarian about its use in animals.
- Achieved complete remission by early 2017.
- Critical confounding factor: He was the only patient in his Keytruda trial cohort to achieve remission, but Keytruda alone can cure a subset of patients with high tumor mutational burden or microsatellite instability.
- As of 2026, Joe reports scaling back fenbendazole to 3 days/week for prevention and remains in remission.
Lifestyle Recommendations
- Diet: Eliminate refined sugars and processed foods; focus on whole foods like vegetables, lean proteins, and healthy fats.
- Exercise: Engage in regular physical activity, tailored to your health status.
- Stress Management: Practice mindfulness, meditation, or other stress-reduction techniques.
- Joe Tippens' official blog (primary source for his full story and ongoing updates): https://mycancerstory.rocks/
- Recent confirmation Joe remains alive and cancer-free (9+ years post-diagnosis): https://healnavigator.com/ask-our-experts/is-joe-tippens-still-alive-in-2024/ (September 2025 update)
Joe Tippens LiveStream, August 2026 - Joe answers your questions about his story
- I do not trust any of the other manufacturers, other than Merck. (Youtube timestamp, 3:10)
- I don't believe that anybody should be taking anything other than the powder, granules from Merck either in the brand name of Panacur C or Safeguard. (Youtube timestamp, 3:40)
- On ivermectin and fenbendazole combination, I am 90% certain is the fenbendazole doing most of the work. (Youtube timestamp, 10:50)
- Why? The one thing that fenbendazole does that none of the other anti-parasitics do, is that it attacks the down-regulators to p53. p53 protein kills cancer cells. The down-regulators are keeping the p53 levels at bay. If you can hit those down-regulators, and increase your levels of p53, I believe that the protocol is a fantastic preventative protocol for cancer. (Youtube timestamp, 11:00)
- My protocol 9 years ago was a 3 days on and 4 days off protocol, because I was worried of the potential liver side-effect. Last year, I found the research that fenbendazole can negatively affect the liver, was at 5,000 times the dosage that we recommend (222 mg/day). (Youtube timestamp, 14:25)
- If somebody is in a aggressive stage 4 cancer scenario, they should double the dose to 444 mg/day for the 1st month or so. If the liver enzymes spike, cut back the dosage. (Youtube timestamp, 16:00)
- The Korean government did a hit piece on me saying that Joe is a fraud as he was taking Keytruda (pembrolizumab) simultaneously with fenbendazole in the same period when he achieved NED (no evidence of disease). Merck did 3 different clinical trials, for Keytruda in metastatic (stage 4) small cell lung cancer (SCLC) but it failed. I'm the only survivor out of the 3 trials. In 2021, Merck went to the FDA and said "Keytruda does not work for metastatic SCLC". For NSCLC (non small cell lung cancer), Keytruda is a great drug. But in my case (SCLC), Keytruda had no impact. The wide metastasis happened after my chemo and radiotherapy. For someone with wide metastatic SCLC, I am the only data outlier in the 75 years history of MD Anderson. That was because of fenbendazole and the other things I was taking. ((Youtube timestamp, 17:00 - 22:00)
Current Versions of the Joe Tippens Protocol (December 2025)
- Fenbendazole: 222 mg daily (1 gram packet of Panacur C or Safe-Guard). Take with food/fats for better absorption. Originally 3 days on/4 days off, later switched to daily.
-
Core supplements
(Vitamin E was removed in later updates due to
interactions):
- Full-spectrum CBD oil: 25–50 mg/day
- Curcumin (bioavailable form): 600 mg/day
- Berberine: 500–600 mg/day (to restrict glucose uptake)
- Fenbendazole 222 mg (1 gm of Panacur™ or Safeguard™) per day every day. Note if you are using liquid - most liquids are 100 mg/ml. You would take 2.2 ml of the liquid.
- ONCO ADJUNCT™ Pathway 1™ - 2-4 ml 2 times a day depending on your weight. High-bioavailability CBD + frankincense.
- ONCO ADJUNCT™ Pathway 2™ - 3 capsules 2 times a day only when you are off chemo. UltraCurcumin + UltraQuercetin + frankincense.
- ONCO ADJUNCT™ Pathway 3™- With each meal - 1 (one) capsule with a light meal and 2 (two) capsules with a heavy meal if you are trying to starve your cancer of sugars. UltraBerberine (taken with meals to mimic metformin effects).
- NEW - ONCO ADJUNCT™ Pathway 4™- 2 Capsules twice a day. EGCG + resveratrol + fisetin + beta-glucans
- Fenbendazole: 222–444 mg daily (up to 1,500 mg/day in aggressive or non-responsive cases), usually 6–7 days/week with 1 day off.
- Ivermectin: 0.5–1 mg/kg body weight, commonly 24–60 mg flat dose (up to 2 mg/kg in aggressive or non-responsive cases), daily or 5–7 days/week, taken with a high-fat meal.
- Mebendazole (prescription human alternative): 100–400 mg daily (some reports up to 1,500 mg); often alternated with or used instead of fenbendazole.
- Bioavailable curcumin: 600–800 mg daily.
- Berberine: 500–1,000 mg daily.
- Vitamin D3 + K2: 2,500–5,000 IU daily.
- Diet and Lifestyle:
- A 2026 study (American Association for Cancer Research), linked Ultra-Processed Foods to Reduced Survival after Cancer. Sugar, starch, saturated fat packed into ultra-processed food not only associated with obesity, diabetes, and heart disease, it also worsens cancer prognosis.
- Another 2026 study published in The BMJ examined how everyday exposure to food preservatives influences cancer risk. The findings were clear — people who consumed more preservatives had higher rates of overall cancer and breast cancer. The findings support recommendations for consumers to favour freshly made, minimally processed foods.
- Weight loss if overweight (low carb, keto diet, intermittent fasting). A 2026 findings published in Nature Communications, insulin resistance has been linked to a 25% higher risk of 12 different types of cancer. Insulin resistance is often caused by obesity and its associated chronic inflammation. Both diabetes and obesity are associated with a higher risk of cancer.
- Adopt a whole-food diet and avoid ultra-processed foods, as recommended by the BMJ 2024 guidelines.
- Eliminate sugar consumption as supported by the BMJ 2023 umbrella review, which recommends reducing free and added sugars to below 25 g/day and limiting sugar-sweetened beverages to less than one serving per week to reduce adverse health effects.
- Additionally, prioritise adequate sleep and effective stress management to support overall health.
Sources:
- Original Joe Tippens protocol and updates (including removal of Vitamin E, Onco-Adjunct Pathways, and UltraBotanica branding): Directly from his blog — https://mycancerstory.rocks/
- "Turbocharged" protocols combining fenbendazole + ivermectin (popularized by Dr. William Makis and patient communities): Numerous testimonials and protocol discussions compiled here — https://www.onedaymd.com/2024/07/ivermectin-articles-and-protocols-for.html
The Science Behind Fenbendazole
Key Scientific Evidence
- Comprehensive review on oral fenbendazole for cancer therapy (mechanisms, preclinical data, human pharmacokinetics, and call for trials): Nguyen J et al. "Oral Fenbendazole for Cancer Therapy in Humans and Animals." Anticancer Research, September 2024 — https://ar.iiarjournals.org/content/44/9/3725 (full text) or https://pubmed.ncbi.nlm.nih.gov/39197912/
- Large compilations of anecdotal case reports (550+ across various cancer types, 2021–2026): https://www.onedaymd.com/2024/02/fenbendazole-cancer-success-stories.html (regularly updated).
Other Key Studies
- 2024 Apr, Rodrigues et al - Repurposing mebendazole against triple-negative breast cancer CNS metastasis
- 2024 Feb, Eid et al - Investigating the Promising Anticancer Activity of Cetuximab and Fenbendazole Combination as Dual CBS and VEGFR-2 Inhibitors and Endowed with Apoptotic Potential
- 2024 Feb, Park et al - The microtubule cytoskeleton: A validated target for the development of 2-Aryl-1H-benzo[d]imidazole derivatives as potential anticancer agents
- 2024 Jan, Matsuo et al - Parbendazole as a promising drug for inducing differentiation of acute myeloid leukemia cells with various subtypes
- 2023, Dec, Iragavarapu-Charyulu et al - A novel treatment to enhance survival for end stage triple negative breast cancer using repurposed veterinary anthelmintics combined with gut‑supporting/immune enhancing molecules
- 2023 Nov, Aliabadi et al - In vitro and in vivo anticancer activity of mebendazole in colon cancer: a promising drug repositioning
- 2023 Nov, Jung et al - Fenbendazole Exhibits Differential Anticancer Effects In Vitro and In Vivo in Models of Mouse Lymphoma
- 2023 Sep, Garg et al - Network pharmacology and molecular docking study-based approach to explore mechanism of benzimidazole-based anthelmintics for the treatment of lung cancer
- 2023 Jun, Mukherjee et al - Ketogenic diet as a metabolic vehicle for enhancing the therapeutic efficacy of mebendazole and devimistat in preclinical pediatric glioma
- 2023 Feb, Lee et al - Benzimidazole and its derivatives as cancer therapeutics: The potential role from traditional to precision medicine.
- 2021 Chiang et al - Fenbendazole Enhancing Anti-Tumor Effect: A Stanford University Case Series.
Joe Tippens’ Story
Important Context: Tippens’ participation in the Keytruda trial may have contributed to his outcome, as immunotherapy is effective in some lung cancer cases. The relative contributions of Keytruda and fenbendazole to his recovery are unclear, highlighting the need for controlled studies.
Case Reports and Anecdotal Evidence
Risks and Considerations
The Joe Tippens Protocol is experimental, and potential risks include:- Side Effects: Fenbendazole may cause liver toxicity or gastrointestinal issues at high doses, though human data is limited [4].
- Drug Interactions: Curcumin’s antioxidant properties may reduce the efficacy of chemotherapy or radiation, which rely on oxidative stress to kill cancer cells [6].
- Lack of Regulation: Fenbendazole for human use is not FDA-approved, and sourcing from veterinary suppliers carries risks of contamination or incorrect dosing.
- Always consult a healthcare provider before starting the protocol, especially if undergoing conventional cancer treatments.
Controversies and Misinformation
The protocol’s popularity surged after Tippens’ story went viral, leading to widespread interest and some misinformation:- 2020 South Korea Fenbendazole Scandal: Misleading claims about fenbendazole’s efficacy led to overuse, with some patients abandoning conventional treatments.
- Misdiagnosis Hypothesis: Some speculate that cancers responsive to fenbendazole may be parasitic infections misdiagnosed as cancer. However, Tippens’ diagnosis was confirmed via biopsy, making this unlikely in his case.
- Anecdotal vs. Scientific Evidence: The protocol’s reliance on personal stories rather than large-scale trials has fueled debate about its validity.
- Readers should approach claims critically and seek information from reputable sources like the National Cancer Institute (NCI) or peer-reviewed journals.
Next Steps
If you’re considering the Joe Tippens Protocol:- Consult a Healthcare Provider: Discuss the protocol’s risks and benefits with an oncologist or integrative medicine specialist.
- Stay Informed: Visit reputable resources like the NCI (cancer.gov) or Independent Medical Alliance, formerly FLCCC (imahealth.org) for updates on fenbendazole research.
- Join Support Groups: Engage with verified communities, such as those on X or cancer forums, to learn from others’ experiences while verifying information.
-
Never abandon conventional oncology care — fenbendazole is at best an adjunct.
-
If you choose to explore it despite the lack of evidence:
-
Use only pharmaceutical-grade product (Lab-tested pure powder).
-
Start at the standard 222 mg/day and increase only if tolerated.
-
Always take with dietary fat for absorption.
-
Consider prescription mebendazole instead (better human safety data).
-
Most promising adjuncts based on mechanistic and anecdotal synergy: ivermectin, berberine, bioavailable curcumin, ketogenic diet, avoid processed foods.
-
Await proper trials — several mebendazole and ivermectin studies are actively recruiting; fenbendazole pilot studies are being planned but none are active yet.
Conclusion
The Joe Tippens Protocol offers hope to some cancer patients, but its evidence is primarily anecdotal and preclinical. While Joe Tippens’ story and case reports are compelling, the protocol’s effectiveness remains unproven without large-scale clinical trials. Potential risks, such as drug interactions and lack of regulation, underscore the need for medical supervision. By combining curiosity with caution, readers can explore this experimental approach responsibly while prioritizing evidence-based care.Frequently Asked Questions: Fenbendazole, Ivermectin and Mebendazole for Cancer
Are ivermectin, fenbendazole, and mebendazole interchangeable?
No. Although all three are antiparasitic drugs and all have attracted interest as potential repurposed cancer therapies, they are not interchangeable.
Ivermectin, fenbendazole, and mebendazole belong to different chemical and pharmacologic contexts and have different:
molecular targets
mechanisms of action
absorption and metabolism
tissue distribution
human safety data
approved medical uses
drug-interaction profiles
evidence supporting potential anticancer effects
Mebendazole and fenbendazole are structurally related benzimidazole compounds, whereas ivermectin belongs to a different drug class known as the avermectins.
Their anticancer mechanisms may overlap in some experimental settings, but overlap does not mean equivalence. For example, laboratory studies have investigated effects on microtubules, glucose metabolism, oxidative stress, signaling pathways, apoptosis, and other cellular processes, but the magnitude and relevance of these effects can differ substantially between compounds.
Most importantly, evidence for one drug cannot simply be transferred to another drug.
A cancer study involving mebendazole does not establish that fenbendazole will produce the same result. Similarly, laboratory activity observed with ivermectin does not establish clinical efficacy for either benzimidazole.
Read more: Cancer Biomarker Map for Fenbendazole, Mebendazole and Ivermectin: A Comparative Mechanistic Analysis for Precision Oncology (2026)
Why are fenbendazole and mebendazole often discussed together?
Fenbendazole and mebendazole are both benzimidazole-class antiparasitic drugs and share some structural and pharmacologic characteristics.
This has led researchers to investigate whether mechanisms observed with one compound might also be relevant to another. However, being in the same broad drug class does not make the drugs clinically equivalent.
Mebendazole has considerably more human clinical experience because it is an established human antiparasitic medicine. Fenbendazole, by contrast, is primarily a veterinary drug and is not an approved human cancer treatment.
Therefore, mebendazole's human safety and pharmacokinetic history should not automatically be used to justify fenbendazole use.
Can ivermectin be substituted for mebendazole or fenbendazole?
No. They should not be viewed as simple substitutes.
Even when two drugs appear to affect a similar biological pathway in laboratory experiments, their concentrations at the tumor, metabolism, toxicity, and ability to achieve biologically relevant exposure in humans may differ.
The clinically relevant question is not simply whether two compounds have an interesting mechanism. It is whether a specific drug at a clinically achievable exposure improves outcomes in patients with a specific cancer.
That question remains unresolved for these repurposed antiparasitic strategies.
Does combining ivermectin with fenbendazole or mebendazole make the treatment stronger?
It is not established that combining them produces a better clinical outcome.
There may be theoretical reasons to investigate combinations, particularly where preclinical studies suggest effects on complementary pathways. However, theoretical synergy is not the same as demonstrated clinical synergy.
Combining multiple repurposed drugs can also make it more difficult to determine:
which compound is producing an effect
which compound is responsible for an adverse event
whether drug interactions alter exposure
whether the combined regimen has an acceptable therapeutic window
Combination strategies should therefore be evaluated through properly designed clinical research rather than assumed to be superior because the individual drugs have promising laboratory mechanisms.
Can evidence for mebendazole be used as evidence for fenbendazole?
Not directly.
Mebendazole and fenbendazole are related benzimidazoles, but they are different compounds.
A positive laboratory study, clinical trial, case report, or observational study involving mebendazole should be attributed to mebendazole, not generalized to fenbendazole.
The same principle applies in reverse.
This distinction is particularly important in cancer repurposing research, where mechanistic similarity can sometimes lead to excessive extrapolation from one drug to another.
Can evidence for ivermectin be combined with evidence for fenbendazole and mebendazole?
The evidence can be compared, but it should not be pooled as though the drugs were one treatment.
A useful comparison asks:
What drug? What cancer? What mechanism? What dose or exposure? What evidence level? What clinical endpoint? What confounders?
This allows researchers and patients to distinguish between a general signal that antiparasitic drugs deserve investigation and evidence that a particular drug benefits patients with a particular cancer.
The distinction is essential because drug repurposing is compound-specific and cancer-specific.
Can fenbendazole, ivermectin, and mebendazole all be described as “anticancer drugs”?
Not at present.
A more accurate description is that they are antiparasitic drugs being investigated or discussed for potential anticancer applications.
Calling them established anticancer drugs implies a level of clinical evidence and regulatory acceptance that does not currently exist for these uses.
Which of the three has the strongest human clinical foundation?
They have different evidence profiles.
Ivermectin has extensive human experience for approved antiparasitic indications, but its use in cancer remains investigational.
Mebendazole is also an established human antiparasitic medicine and has a larger body of human clinical experience than fenbendazole. It has been investigated in cancer studies, but evidence of meaningful anticancer efficacy remains insufficient for it to become standard oncology treatment.
Fenbendazole has much less established human clinical experience because it is a veterinary antiparasitic rather than an approved human medicine. Evidence supporting its use in cancer remains largely preclinical and anecdotal, including case reports.
Therefore, having more human safety experience with ivermectin or mebendazole should not be interpreted as proof of anticancer efficacy.
Does being in the same drug class mean the drugs should have the same anticancer effect?
No.
Drug classes provide useful information about chemical structure and pharmacology, but individual compounds can behave very differently in humans.
Two related drugs can differ in:
potency
target selectivity
bioavailability
half-life
metabolism
tissue penetration
achievable concentration
toxicity
drug interactions
For cancer treatment, these differences can be clinically decisive.
What is the safest way to interpret the three drugs?
The most scientifically defensible approach is to evaluate each drug separately and then compare the evidence.
Same broad therapeutic category ≠ same drug ≠ same mechanism ≠ same clinical effect.
Fenbendazole, ivermectin, and mebendazole should therefore be treated as three separate research questions, even when investigators are exploring related biological mechanisms.
Can fenbendazole or ivermectin cure cancer?
No. There is currently insufficient high-quality clinical evidence to conclude that fenbendazole or ivermectin can cure cancer.
Individual case reports and patient-reported cancer responses can be scientifically interesting and may generate hypotheses, but they cannot establish that a drug caused a remission. Patients may also receive conventional treatment, other repurposed drugs, supplements, dietary interventions, or have disease characteristics that affect the outcome.
Why are fenbendazole and ivermectin being studied in cancer?
Both drugs have attracted research interest because laboratory studies have identified potentially relevant anticancer mechanisms.
Depending on the experimental model, researchers have reported effects involving cell-cycle regulation, cytoskeletal function, cellular metabolism, oxidative stress, apoptosis, autophagy, intracellular signaling, and tumor–immune interactions.
These findings provide biological hypotheses, but activity in cultured cells or animal models does not automatically translate into effective treatment in humans.
Is fenbendazole approved for use in humans?
No. Fenbendazole is a veterinary antiparasitic drug and is not approved by the U.S. FDA as a human cancer treatment.
Human safety, pharmacokinetics, optimal dosing, and anticancer efficacy have not been established to the standards required for an approved oncology therapy.
Is ivermectin approved for cancer?
No. Ivermectin is an established human antiparasitic medicine for specific approved indications, but cancer treatment is not an approved indication.
Its potential anticancer effects remain investigational.
What is the strongest human evidence for ivermectin in cancer?
Human evidence remains limited.
A 2026 prospective observational cohort reported outcomes in patients receiving ivermectin plus mebendazole. However, the study was not randomized and included substantial patient-reported outcome data. The publication also now carries an Expression of Concern related to data-integrity and ethical-verification issues.
The findings should therefore be regarded as hypothesis-generating rather than proof that the treatment is effective.
What is the strongest human evidence for fenbendazole?
Human evidence for fenbendazole is particularly limited.
Published case reports and small case series have described patients who took fenbendazole alongside other treatments and subsequently experienced remission or disease control.
These reports may be useful for generating research questions, but they cannot determine whether fenbendazole caused the response.
Should these drugs be used instead of standard cancer treatment?
No.
Patients should not stop or delay evidence-based cancer treatment because of claims about fenbendazole, ivermectin, mebendazole, or any other repurposed drug.
Cancer is heterogeneous, and appropriate treatment depends on cancer type, stage, biomarkers, previous treatments, overall health, and treatment goals.
Are the doses discussed online proven cancer doses?
No.
Doses circulated through patient communities or published anecdotal protocols should not be treated as validated oncology dosing.
Human clinical trials are needed to establish appropriate oncology dosing.
What are the main safety concerns?
Safety depends on the drug, dose, formulation, duration, the patient's liver and kidney function, other medicines being taken, and the underlying cancer.
Ivermectin and mebendazole have established human uses for certain parasitic infections, but that does not establish safety or efficacy when they are used experimentally for cancer.
Fenbendazole has substantially less human safety information because it is not an approved human medicine.
Potential drug interactions and organ toxicity should be reviewed by a qualified clinician rather than inferred from anecdotal reports.
Does laboratory evidence mean the drugs work in people?
No.
Cancer cells in a laboratory are not equivalent to tumors inside a human body.
Drug concentration, absorption, metabolism, tissue penetration, tumor heterogeneity, immune response, toxicity, and drug resistance can all affect whether a laboratory finding becomes clinically useful.
Which cancers may be affected by these drugs?
Preclinical research has investigated these compounds across multiple cancer types, including breast, lung, colorectal, prostate, brain, and other malignancies.
However, a laboratory signal in a particular cancer does not mean that the drug is clinically effective in that cancer.
At present, there is no established cancer indication for fenbendazole, ivermectin, or mebendazole based on sufficient clinical evidence.
Where does the evidence stand today?
There is substantial mechanistic and preclinical interest, an expanding collection of human case reports and observational data, and continuing interest in drug repurposing.
However, the evidence remains insufficient to establish fenbendazole, ivermectin, or mebendazole as standard cancer treatments.
The critical next step is rigorous, independently verified clinical research.
OneDayMD Evidence Note
The presence of a published study, case report, testimonial, or mechanistic finding does not mean that a treatment has been proven effective.
We distinguish between:
Preclinical evidence → Human observational evidence → Case reports/series → Randomized clinical evidence
These evidence categories answer different questions and should not be treated as interchangeable.
Medical Disclaimer
This article is provided for educational and research purposes only and is not personal medical advice.
Fenbendazole, ivermectin, and mebendazole should not be used to replace or delay evidence-based cancer treatment. Discuss any off-label or investigational therapy with an appropriately qualified healthcare professional.
- Mebendazole vs fenbendazole for cancer
- Ivermectin vs Fenbendazole for Cancer
- Best Ivermectin Dosage for Humans with Cancer or Different Cancer Types
- Best Fenbendazole Dosage for Humans: Safety, Side Effects and Efficacy Examined
- Potential Role of Fenbendazole and Ivermectin in the Treatment of Stage 4 Pancreatic Cancer: A Compilation of Case Reports and Mechanistic Insights (2025)
- Turbo Cancers Debunked: Linked to COVID Jabs
- Ivermectin and Fenbendazole: Treating Turbo Cancer
- Top 10 Cancer Fighting Supplements
- 20 Best Alternative Cancer Treatments 2026
Researched and approved by Dr. Peter McCullough.
- Prescribed by licensed medical professionals
- Compounded and dispensed by a licensed US-based pharmacy
- Approved for human use
.png)
IVM and fenbendazole are winners in cancer treatment, as my husband can testify. Unfortunately there is someone on X impersonating Joe Tippens, whose real Facebook account says is the only social media account he has. They are using Tippens' name to con people out of hundreds of dollars for IVM and fenbendazole, scamming the sick and the elderly. I have tried to report him to X but can't get through their AI wall. So be careful and DO NOT order from the grifter on X!
ReplyDelete